Recent advancements by researchers at Karolinska Institutet and KTH Royal Institute of Technology have led to a refined technique for generating insulin-producing cells from human stem cells. Their study highlights the efficacy of these cells in regulating blood sugar levels during laboratory experiments and demonstrates their potential to reverse diabetes in mouse models.
Groundbreaking Methodology
Per-Olof Berggren, PhD, a professor at the Department of Molecular Medicine and Surgery at Karolinska Institutet, emphasized the significance of their findings. “We have developed a method that reliably produces high-quality insulin-producing cells from multiple human stem cell lines,” he stated. This innovation paves the way for personalized cell therapies that could mitigate the risks of immune rejection. Berggren and Siqin Wu, PhD, of Spiber Technologies AB, are the co-corresponding authors of the study published in Stem Cell Reports, entitled “An optimized protocol for efficient derivation of pancreatic islets from multiple human pluripotent stem cell lines.”
Understanding Type 1 Diabetes
Type 1 diabetes (T1D) arises when the immune system attacks the insulin-producing beta cells in the pancreas, resulting in the body’s inability to absorb glucose effectively. This condition leads to a loss of glycemic control, as described in the study.
One promising treatment approach involves replacing these damaged cells with new, functional ones. However, previous techniques for generating insulin-producing cells from stem cells have yielded inconsistent results. While stem cell therapy for T1D is currently under investigation in various clinical trials, earlier methods often resulted in a mix of desired and undesired cell types, increasing the risk of complications. Furthermore, the insulin-producing cells generated were frequently immature and unable to respond adequately to glucose levels.
Challenges in Cell Therapy
The research team pointed out that the effectiveness of cell therapy for T1D hinges on the successful differentiation of stem cells into fully functional pancreatic islets. Previous differentiation protocols have shown variable efficiency across different human pluripotent stem cell (hPSC) lines. The authors noted, “Differentiation beyond the stage (S) 4 pancreatic progenitor (PP) stage often results in heterogeneous cultures containing both proliferative non-endocrine and immature endocrine cells, raising the risk of cyst or tumor formation.”
Optimized Production Process
The newly optimized method introduced by Berggren and his colleagues yields insulin-producing cells that are both purer and more mature than those generated through earlier techniques. In laboratory settings, these cells demonstrated the ability to secrete insulin effectively and exhibited a strong response to glucose stimuli. When transplanted into mice with streptozotocin (STZ)-induced diabetes, the animals gradually regained their ability to control blood sugar levels.
Researchers achieved this success by refining the culture steps and allowing the cells to form three-dimensional clusters independently, which helped eliminate many unwanted cell types. “Single-cell analyses confirm that the SC-islets are devoid of non-endocrine cell populations before and after transplantation,” the team stated.
Innovative Transplantation Technique
The transplantation process was conducted in the anterior chamber of the eye (ACE), a site providing a transparent and accessible environment for non-invasive monitoring of the engrafted SC-islets through the cornea. This method is not only straightforward but also minimally invasive. The team reported that intraperitoneal glucose tolerance tests (IPGTT) conducted three, four, and six months post-transplantation revealed improved glucose regulation over time. Remarkably, SC-islet transplantation reversed hyperglycemia within three months, and by the five- to six-month mark, blood glucose levels had dipped slightly below pre-STZ baselines.
Monitoring and Future Prospects
Berggren remarked on the importance of their technique for monitoring the development and functionality of the cells over time with minimal invasiveness. The researchers observed that the cells gradually matured post-transplantation, maintaining their blood sugar regulation capabilities for several months—an encouraging sign for future therapeutic applications.
Fredrik Lanner, PhD, a professor at the Department of Clinical Science, Intervention, and Technology at Karolinska Institutet, highlighted the potential of this research to address prior obstacles in developing stem cell-based treatments for T1D. The authors concluded their report by stating, “Our protocol generated glucose-responsive SC-islets from all eight hPSC lines tested, demonstrating potential for autologous applications. Our efficient differentiation protocol represents a crucial step toward autologous cell therapy, although further research is necessary to fully realize this ambition.”
Key Takeaways
- A refined method for creating insulin-producing cells from human stem cells has been developed.
- The new protocol leads to more mature and functional cells, improving outcomes in laboratory models.
-
Transplantation in the anterior chamber of the eye allows for effective monitoring and minimal invasiveness.
-
This research represents a significant advancement toward personalized treatments for Type 1 diabetes.
In conclusion, the ongoing research into stem cell-derived insulin-producing cells showcases a promising frontier in the fight against Type 1 diabetes. With further development and refinement, these breakthroughs may lead to effective, personalized treatment options that enhance the quality of life for those affected by this condition.
Read more → www.genengnews.com